Advertisement

Adherence to Antiretroviral Therapy Among Incarcerated Persons with HIV: Associations with Methadone and Perceived Safety

  • Gabriel J. CulbertEmail author
  • Agung Waluyo
  • Melinda Wang
  • Tissa Aulia Putri
  • Alexander R. Bazazi
  • Frederick L. Altice
Original Paper

Abstract

With adequate support, people with HIV (PWH) may achieve high levels of adherence to antiretroviral therapy (ART) during incarceration. We examined factors associated with ART utilization and adherence among incarcerated PWH (N = 150) in Indonesia. ART utilization was positively associated with HIV status disclosure (adjusted odds ratio [aOR] = 5.5, 95% CI 1.2–24.1, p = 0.023), drug dependency (aOR = 3.9, 95% CI 1.2–12.6, p = 0.022), health service satisfaction (aOR = 3.2, 95% CI 1.7–6.2, p < 0.001), and perceived need for medical treatment (aOR = 1.6, 95% CI 1.1–2.5, p = 0.011), and negatively associated with chance locus of control (aOR = 0.3, 95% CI 0.1–0.7, p = 0.013). Most participants utilizing ART (74.5%) reported less than “perfect” ART adherence. ART adherence was independently associated with perceived personal safety (β = 0.21, 95% CI 0.01–0.40, p = 0.032) and methadone utilization (β = 0.84, 95% CI 0.10–1.67, p = 0.047). PWH receiving methadone had a sixfold higher adjusted odds of being highly-adherent to ART (aOR = 6.3, 95% CI 1.1–35.7, p = 0.036). Interventions that increase methadone utilization and personal safety may improve ART adherence among incarcerated PWH.

Keywords

Adherence Antiretroviral therapy HIV Methadone Prisons Substance use 

Notes

Acknowledgements

We thank study participants for generously sharing of their time and gratefully acknowledge operational assistance from the Directorate General of Corrections, Republic of Indonesia. We thank Abbott laboratories (formerly Alere) for equipment donated to the study.

Funding

This study was supported by NIH awards for research training (NIDA K23 DA041988 to GJC) and career development (NIDA K24 DA017072 to FLA).

Compliance with Ethical Standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical Approval

All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.CrossRefGoogle Scholar
  2. 2.
    Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;388(10049):1103–14.CrossRefGoogle Scholar
  3. 3.
    Wohl DA, Stephenson BL, Golin CE, Kiziah CN, Rosen D, Ngo B, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus—infected prison inmates. Clin Infect Dis. 2003;36(12):1572–6.CrossRefGoogle Scholar
  4. 4.
    Young JD, Patel M, Badowski M, Mackesy-Amiti ME, Vaughn P, Shicker L, et al. Improved virologic suppression with HIV subspecialty care in a large prison system using telemedicine: an observational study with historical controls. Clin Infect Dis. 2014;59(1):123–6.CrossRefGoogle Scholar
  5. 5.
    Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):721–9.CrossRefGoogle Scholar
  6. 6.
    Uthman OA, Oladimeji O, Nduka C. Adherence to antiretroviral therapy among HIV-infected prisoners: a systematic review and meta-analysis. AIDS Care. 2017;29(4):489–97.CrossRefGoogle Scholar
  7. 7.
    Fu JJ, Bazazi AR, Altice FL, Mohamed MN, Kamarulzaman A. Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers. PLoS ONE. 2012;7(9):e44249.CrossRefGoogle Scholar
  8. 8.
    Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS ONE. 2013;8(3):e59643.CrossRefGoogle Scholar
  9. 9.
    Telisinghe L, Charalambous S, Topp SM, Herce ME, Hoffmann CJ, Barron P, et al. HIV and tuberculosis in prisons in sub-Saharan Africa. Lancet. 2016;388(10050):1215–27.CrossRefGoogle Scholar
  10. 10.
    Culbert GJ, Crawford FW, Murni A, Waluyo A, Bazazi AR, Sahar J, et al. Predictors of mortality within prison and after release among persons living with HIV in Indonesia. Res Rep Trop Med. 2017;8:25–35.CrossRefGoogle Scholar
  11. 11.
    Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with human immunodeficiency virus on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities. Clin Infect Dis. 2018;66(10):1487–91.CrossRefGoogle Scholar
  12. 12.
    Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91.CrossRefGoogle Scholar
  13. 13.
    Bick J, Culbert G, Al-Darraji HA, Koh C, Pillai V, Kamarulzaman A, et al. Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. Int J Prison Health. 2016;12(4):253–69.CrossRefGoogle Scholar
  14. 14.
    Muessig KE, Rosen DL, Farel CE, White BL, Filene EJ, Wohl DA. “Inside these fences is our own little world”: prison-based hiv testing and hiv-related stigma among incarcerated men and women. AIDS Educ Prev. 2016;28(2):103–16.CrossRefGoogle Scholar
  15. 15.
    Hinduan ZR, Suherman H, Pinxten WJ, Alisjahbana B, Hospers HJ. HIV-related knowledge and attitudes among Indonesian prison officers. Int J Prison Health. 2013;9(2):92–102.CrossRefGoogle Scholar
  16. 16.
    Culbert GJ. Violence and the perceived risks of taking antiretroviral therapy in US jails and prisons. Int J Prison Health. 2014;10(2):94–110.CrossRefGoogle Scholar
  17. 17.
    Shalihu N, Pretorius L, van Dyk A, Vander Stoep A, Hagopian A. Namibian prisoners describe barriers to HIV antiretroviral therapy adherence. AIDS Care. 2014;26(8):968–75.CrossRefGoogle Scholar
  18. 18.
    Culbert GJ, Waluyo A, Iriyanti M, Muchransyah AP, Kamarulzaman A, Altice FL. Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice. Drug Alcohol Depend. 2015;149:71–9.CrossRefGoogle Scholar
  19. 19.
    Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy. 2014;25(5):845–52.CrossRefGoogle Scholar
  20. 20.
    Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefGoogle Scholar
  21. 21.
    Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. Lancet HIV. 2018;5(2):e96–106.CrossRefGoogle Scholar
  22. 22.
    Joint United Nations Programme on HIV/AIDS. The Gap Report. Geneva: UNAIDS, 2014.Google Scholar
  23. 23.
    Morineau G, Bollen LJ, Syafitri RI, Nurjannah N, Mustikawati DE, Magnani R. HIV prevalence and risk behaviours among injecting drug users in six indonesian cities implications for future HIV prevention programs. Harm Reduct J. 2012;9(1):37.CrossRefGoogle Scholar
  24. 24.
    Blogg S, Utomo B, Silitonga N, Ayu N, Hidayati D, Sattler G. Indonesian national inmate bio-behavioral survey for HIV and syphilis prevalence and risk behaviors in prisons and detention centers, 2010. SAGE Open. 2014.  https://doi.org/10.1177/2158244013518924.CrossRefGoogle Scholar
  25. 25.
    Nelwan EJ, Van Crevel R, Alisjahbana B, Indrati AK, Dwiyana RF, Nuralam N, et al. Human immunodeficiency virus, hepatitis B and hepatitis C in an Indonesian prison: prevalence, risk factors and implications of HIV screening. Trop Med Int Health. 2010;15(12):1491–8.CrossRefGoogle Scholar
  26. 26.
    Nelwan EJ, Isa A, Alisjahbana B, Triani N, Djamaris I, Djaja I, et al. Routine or targeted HIV screening of Indonesian prisoners. Int J Prison Health. 2016;12(1):17–26.CrossRefGoogle Scholar
  27. 27.
    Nelwan EJ, Indrati AK, Isa A, Triani N, Alam NN, Herlan MS, et al. Effect of HIV prevention and treatment program on HIV and HCV transmission and HIV mortality at an Indonesian narcotic prison. Southeast Asian J Trop Med Public Health. 2015;46(5):880–91.PubMedGoogle Scholar
  28. 28.
    Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Rhodes T. The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85–94.CrossRefGoogle Scholar
  30. 30.
    Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228–48.CrossRefGoogle Scholar
  31. 31.
    Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17(Suppl 2):S156–70.CrossRefGoogle Scholar
  32. 32.
    Strathdee SA, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. 2015;26:S27–32.CrossRefGoogle Scholar
  33. 33.
    Booth RE, Dvoryak S, Sung-Joon M, Brewster JT, Wendt WW, Corsi KF, et al. Law enforcement practices associated with HIV infection among injection drug users in Odessa, Ukraine. AIDS Behav. 2013;17(8):2604–14.CrossRefGoogle Scholar
  34. 34.
    Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.CrossRefGoogle Scholar
  35. 35.
    Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193–201.CrossRefGoogle Scholar
  36. 36.
    Culbert GJ, Williams AB. Cultural adaptation of a medication adherence intervention with prisoners living with HIV in Indonesia: a pragmatic approach to intervention development. J Assoc Nurses AIDS Care. 2018;29(3):454–65.CrossRefGoogle Scholar
  37. 37.
    Williams AB, Burgess JD, Danvers K, Malone J, Winfield SD, Saunders L. Kitchen table wisdom: a Freirian approach to medication adherence. J Assoc Nurses AIDS Care. 2005;16(1):3–12.CrossRefGoogle Scholar
  38. 38.
    Degroot AM, Dannenburg L, Vanhell JG. Forward and backward word translation by bilinguals. J Mem Lang. 1994;33(5):600–29.CrossRefGoogle Scholar
  39. 39.
    Chatfield A, Javetski G, Lesh N. CommCare Evidence Base. Dimagi; 2013.Google Scholar
  40. 40.
    Flaming A, Canty M, Javetski G, Lesh N. The CommCare evidence base for frontline workers. 2015.Google Scholar
  41. 41.
    Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.CrossRefGoogle Scholar
  42. 42.
    Culbert GJ, Earnshaw VA, Swasti Wulanyani NM, Wegman MP, Waluyo A, Altice FL. Correlates and experiences of HIV stigma in prisoners living with HIV in Indonesia: a mixed-method analysis. J Assoc Nurses AIDS Care. 2015;26(6):743–57.CrossRefGoogle Scholar
  43. 43.
    Wallston KA, Strudler Wallston B, DeVellis R. Development of the multidimensional health locus of control (MHLC) scales. Health Educ Monogr. 1978;6(1):160–70.CrossRefGoogle Scholar
  44. 44.
    Wallston KA. The validity of the multidimensional health locus of control scales. J Health Psychol. 2005;10(5):623–31.CrossRefGoogle Scholar
  45. 45.
    Institute of Behavioral Research. Texas Christian University Drug Screen V. Fort Worth: Texas Christian University, Institute of Behavioral Research; 2014.Google Scholar
  46. 46.
    Cortes A, Hunt N, McHale S. Development of the scale of perceived social support in HIV (PSS-HIV). AIDS Behav. 2014;18(12):2274–84.CrossRefGoogle Scholar
  47. 47.
    Holzemer WL, Henry SB, Nokes KM, Corless IB, Brown MA, Powell-Cope GM, et al. Validation of the sign and symptom check-list for persons with HIV disease (SSC-HIV). J Adv Nurs. 1999;30(5):1041–9.CrossRefGoogle Scholar
  48. 48.
    Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.CrossRefGoogle Scholar
  49. 49.
    Lazzarini Z, Altice FL. A review of the legal and ethical issues for the conduct of HIV-related research in prisons. AIDS Public Policy J. 2000;15(3–4):105–35.PubMedGoogle Scholar
  50. 50.
    Degenhardt L, Mathers BM, Wirtz AL, Wolfe D, Kamarulzaman A, Carrieri MP, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25(1):53–60.CrossRefGoogle Scholar
  51. 51.
    Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Health. 2016;1(2):e000010.CrossRefGoogle Scholar
  52. 52.
    Joint United Nations Programme on HIV/AIDS. Country Snapshot 2018: Indonesia. UNAIDS Regional Support Team for Asia and the Pacific and AIDS Data Hub: 2018.Google Scholar
  53. 53.
    Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (Lond, Engl). 2009;23(9):1035.CrossRefGoogle Scholar
  54. 54.
    Culbert GJ, Bazazi AR, Waluyo A, Murni A, Muchransyah AP, Iriyanti M, et al. The influence of medication attitudes on utilization of antiretroviral therapy (ART) in Indonesian prisons. AIDS Behav. 2016;20(5):1026–38.CrossRefGoogle Scholar
  55. 55.
    Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefGoogle Scholar
  56. 56.
    Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;26:1094.CrossRefGoogle Scholar
  57. 57.
    Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res. 2009;15(2):107–12.CrossRefGoogle Scholar
  58. 58.
    White BL, Golin CE, Grodensky CA, Kiziah CN, Richardson A, Hudgens MG, et al. Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study. AIDS Behav. 2015;19(1):128–36.CrossRefGoogle Scholar
  59. 59.
    Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62(8):1043–8.CrossRefGoogle Scholar
  60. 60.
    Gray RT, Reyes J, Nadjib M, Harimurti P, Wilson DP. Assessment of the allocation of HIV funding in Indonesia. World Bank; 2012.Google Scholar
  61. 61.
    Kouyoumdjian FG, McIsaac KE, Liauw J, Green S, Karachiwalla F, Siu W, et al. A systematic review of randomized controlled trials of interventions to improve the health of persons during imprisonment and in the year after release. Am J Public Health. 2015;105(4):e13–33.CrossRefGoogle Scholar
  62. 62.
    Farhoudi B, Alipour A, Ghodrati S, Seyedalinaghi S, Zanganeh M, Mohraz M. Barriers to adherence to antiretroviral treatment among inmates of a prison in Tehran, Iran: a qualitative study. Arch Clin Infect Dis. 2018;13(2):e57911.  https://doi.org/10.5812/archcid.57911.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Health Systems Science, College of NursingUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Center for HIV/AIDS Nursing Research, Faculty of NursingUniversitas IndonesiaDepokIndonesia
  3. 3.Department of Medicine, Section of Infectious Diseases, AIDS ProgramYale University School of MedicineNew HavenUSA
  4. 4.Department of Psychiatry, San Francisco School of MedicineUniversity of CaliforniaSan FranciscoUSA
  5. 5.Department of Epidemiology of Microbial DiseasesYale University School of Public HealthNew HavenUSA
  6. 6.Centre of Excellence for Research in AIDS (CERiA)University of MalayaKuala LumpurMalaysia

Personalised recommendations